Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Casein micelle as nano-capsular

This article was originally published in The Tan Sheet

Executive Summary

Casein micelles (CM) have potential to serve as nano-vehicles for added nutraceuticals, according to an article published online Nov. 3 by Food Hydrocolloids. From their study of fat-soluble vitamin D2, Efrat Semo, et al., say, "We have demonstrated for the first time, the possibility to load a nutraceutical compound in CM, utilizing the natural self-assembly tendency of bovine caseins. The vitamin was about 5.5 times more concentrated within the micelles than in the serum where it was only present bound to residual soluble caseins." The authors go on to say "milk fortified with such vitamin D2-enriched rCM [re-assembled micelles] accounting for only 0.6% of the total milk casein would contain about one third of the vitamin D2 recommended daily allowance for adults in a single glass of milk"...

You may also be interested in...

Health And Wellness Trademark Review 19 January, 2021

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Europe's CBD Market In 2020: Narcotic Vs Novel Food

INFOGRAPHIC: An interactive timeline of selected HBW Insight coverage of the growing European CBD dietary supplements market in 2020. The timeline covers the main events of a rollercoaster 12 months, including the European Commission’s indecision on whether to classify CBD as narcotic or novel food and how the path forward became clear in the UK.

Servier and MiNA Target Neurodegenerative Disease With Novel RNA Therapy

Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts